Plexāā Shines with Three Finalist spots at the Prestigious MedTech Innovator Program, the world’s Largest MedTech Accelerator
[Toronto, Canada, October 2024] – Plexāā, a pioneering UK MedTech company, is excited to announce that it has reached three finals in the prestigious MedTech Innovator program, the largest and most successful accelerator in the medical technology sector in the world. This achievement highlights Plexāā’s dedication to innovation and excellence in improving surgical outcomes.
Out of more than 1,000 applicants, Plexāā secured a spot in the esteemed cohort of just 64 startups. MedTech Innovator is known for its impressive track record, having helped graduates bring over 350 products to market and raise more than $8 billion in follow-on funding, transforming millions of lives worldwide.
Throughout the 5-months long program, Plexāā reached three finals: it secured a top 5 position in the pitch competitions in Dublin and Mountain View, California, and won a spot in the top 4 of the prestigious Best Medtech Video competition, held last week in Toronto during the MedTech Innovator conference
“Our recognition in multiple finals at MedTech Innovator is a tremendous honor,” said Dr. Saahil Mehta, Plastic Surgeon and Founder of Plexāā. “These achievements not only validate our innovative solutions but also enhance our ability to deliver advancements that improve surgical outcomes for patients, particularly those undergoing breast surgery.”
Plexāā’s flagship device, BLOOM⁴³, enables patients to supraphysiologically precondition their skin, significantly reducing the risk of wound healing complications such as infection and skin necrosis, which affect 1 in 3 women undergoing breast surgery.
As part of accelerator’s journey, Plexāā has benefited from the mentorship provided by industry strategic leaders at Gore Medical and Johnson & Johnson, further enhancing their capabilities to access new markets and foster strategic collaborations.
For more information about Plexāā and its groundbreaking work, please visit www. or contact us at marketing@plexaa.com.
About Plexāā
Plexāā is a pioneering UK MedTech company focused on improving surgical outcomes through innovative solutions. Their flagship device, BLOOM⁴³ enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect 1 in 3 women undergoing breast surgery.
BLOOM⁴³ is the world’s first fully wearable device worn next to the skin before breast surgery. By gently warming the area to stimulate the release of Heat Shock Proteins (HSPs). These naturally occurring proteins cause the release of carbon monoxide into the tissue which vasodilates the blood vessels and improves the blood flow to the skin. This improved blood flow primes the skin to heal and has been shown to prevent wound healing complications in proof-of-concept clinical trials.
Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes.
Media Contact:
marketing@plexaa.com
